OncoMatch/Clinical Trials/NCT07472153
PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer
Is NCT07472153 recruiting? Yes, currently enrolling (May 2026). This Phase 2/3 trial studies multiple treatments including PD-1 antibody and PD-L1 antibody for metastatic cervical cancer.
Treatment: PD-1 antibody · PD-L1 antibody · Chemotherapy and bevacizumab (CT-BEV) — This is a randomized trial evaluating the results of using of PD-1 and PD-L1 immune checkpoint inhibitors combined with chemotherapy, with or without bevacizumab, in patients with metastatic, persistent, and recurrent cervical cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Cervical Cancer
Biomarker criteria
Required: PD-L1 (CD274) any tested (testing required; no eligibility threshold specified)
Disease stage
Required: Stage IVB, IIB, IIIA, IIIB, IVA, IA (FIGO 2018)
Metastatic cervical cancer (stage IVB according to FIGO (International Federation of Gynaecology and Obstetrics) 2018); Persistent cervical cancer (primary incurability after radical treatment for stages IIB-IVA cervical cancer according to FIGO 2018); Reccurent cervical cancer (first recurrence after completed radical treatment for IA-IVB cervical cancer according to FIGO 2018)
Performance status
ECOG 0–1(Restricted strenuous activity)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify